Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites

By Chan S.L.F.   Pallett A.L.   Clews J.   Ramsden C.A.   Chapman J.C.   Kane C.   Dunne M.J.   Morgan N.G.  

European Journal of Pharmacology, Vol. 355, Iss. 1, 1998-08 ,pp. : 67-76

Elsevier

Access to resources Recommend Favorite

Imidazoline binding sites in Huntington's and Parkinson's disease putamen

By Reynolds G.P.   Boulton R.M.   Pearson S.J.   Hudson A.L.   Nutt D.J.  

European Journal of Pharmacology, Vol. 301, Iss. 1, 1996-04 ,pp. : 19-21

Elsevier

Access to resources Recommend Favorite

Imidazoline Binding Sites and Receptors in Cardiovascular Tissue - an investigation into their relationship to imidazoline, 2 and H 3 receptors

By Molderings G.J.   Gothert M.  

General Pharmacology, Vol. 32, Iss. 1, 1999-01 ,pp. : 17-22

Elsevier

Access to resources Recommend Favorite

Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I 1 and I 2 binding sites

By Coupry I.   Armsby C.C.   Alper S.L.   Brugnara C.   Parini A.  

European Journal of Pharmacology, Vol. 295, Iss. 1, 1996-01 ,pp. : 109-112

Elsevier

Access to resources Recommend Favorite

Polyclonal anti-idiotypic antibodies to idazoxan and their interaction with human brain imidazoline binding sites

By Bennai F.   Greney H.   Vonthron C.   Bousquet P.   Dontenwill M.  

European Journal of Pharmacology, Vol. 306, Iss. 1, 1996-06 ,pp. : 211-218

Elsevier

Access to resources Recommend Favorite